Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(Sulfanylacetyl)Tyrosylprolylmethioninamide is a synthetic oligopeptide composed of sulfanylacetyl, tyrosine, proline, and methionine amide residues. It belongs to the class of organic compounds known as oligopeptides. This compound functions as an inhibitor of lethal factor (LF), a protease component of the anthrax toxin produced by Bacillus anthracis. LF cleaves mitogen-activated protein kinase kinases (MAPKKs or MAP2Ks), disrupting cellular signaling and leading to rapid cell death in macrophages. The peptide itself is not toxic but acts as an inhibitor that can block the activity of LF, potentially preventing its cytotoxic effects[1]. Its primary research application has been in studying anthrax toxin mechanisms and potential therapeutic interventions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(Sulfanylacetyl)Tyrosylprolylmethioninamide.